SGLT-2 Inhibitors

SGLT-2 Inhibitors in the Treatment of Type 2 Diabetes: Methodology and Monitoring Impact

Print This Post Print This Post

CME Information

1


Program Overview

SGLT-2 Inhibitors in the Treatment of Type 2 Diabetes: Methodology and Monitoring Impact is planned as part of a real-time virtual grand rounds series that captures the spirit of a traditional in-person live grand rounds meeting. The content of these programs will all relate to the care of some aspect of diabetes and/or one of its related conditions or comorbidities. The session will consist of faculty presentations of didactic material which will be enhanced by discussions about clinical interpretations and applications.

Accreditation/Designation Statements

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Primary Care Network and PlatformQ Health Education, LLC. Primary Care Network is accredited by the ACCME to provide continuing medical education for physicians.

Live Online Activity: Wednesday August 10, 2016 from 11:00AM – 12:00PM ET.

Primary Care Network designates this live activity for a maximum of 1 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Online On-Demand Enduring Material

Primary Care Network designates this enduring material for a maximum of 1 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

The enduring material will be available from August 10, 2016 – February 10, 2017.

ABIM MOCPNGBadgeABIMMOC

The ACCME (Accreditation Council for Continuing Medical Education) and the American Board of Internal Medicine (ABIM) have collaborated to simplify the integration of Maintenance of Certification (MOC) and accredited CME. This collaboration expands the number and diversity of accredited CME activities registered in ABIM’s MOC program, offering ABIM Board Certified physicians more options for receiving MOC points through their participation in CME activities.

Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1 MOC point in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit. Upon completion, your information will be shared with ABIM through Primary Care Network’s ACCME Program and Activity Reporting System (PARS).

 

Learning Objectives

At the conclusion of this activity, participants will be able to:

  • Discuss SGLT-2 physiology especially in the kidney and how it could be targeted as part of the treatment of hyperglycemia in type 2 diabetes
  • Demonstrate the possible integration of SGLT2 inhibitors into a comprehensive glycemic treatment program for type 2 diabetes
  • Identify the risks and benefits of SGLT2 inhibitors to optimally and safety use them, when indicated, to achieve therapeutic goals

Jointly provided by Primary Care Network, PlatformQ Health Education, LLC and its collaborating partner Joslin Diabetes Center.

PCN_web joslin_diabetes_center_logo

 

click-here


Participant will need to initially
 complete a short registration form with Diabetes Series Live to participate in this activity. Future participation in Diabetes Series Live activities will allow you to skip the registration process and only require you to log-in.

Published July 15, 2016